More Pain For Biotechs Ahead: Valeant’s “Astronomical” Price Increases Take Center Stage; Pfizer Gets Dragged In
by Tyler Durden
ZeroHedge.com
10/04/2015
Late last week, after looking at Valeant soaring default risk as measured by the price of its blowing out CDS, soaring to over 30% even as its stock prices was surging, we wondered – does someone know something? It appears someone may have known that this weekend, the same Andrew Pollack whose NYT article exposing Turing’s 5000% price increase resulted in Hillary Clinton promising to cap specialty biotech prices if elected, has come back for round two and after taking aim at Shkreli and Turing, much to the chagrin of Bill Ackman, Pollack is now taking aim at the biggest culprit: Valeant Pharmaceutcals.
The Rest…HERE